Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02830282 · ClinicalTrials.gov registry record
Surveillance Markers of Utility for Recurrence After Neoadjuvant Chemotherapy for Breast Cancer
A clinical trial, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- 21
- Enrollment target
NCT02830282: Completed study, sponsored by Abramson Cancer Center at Penn Medicine.
NCT02830282 is a clinical trial that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02830282 has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- 21 participants
- Enrollment target
Study Summary
This is a nested multicenter, prospective cohort study within the I-SPY 2 TRIAL for women undergoing neoadjuvant chemotherapy for primary breast cancer who are also undergoing definitive surgical resection and have clinical or radiographic evidence of residual tumor at the completion of chemotherapy.
Interventions
- OTHER Blood Collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2013-07 |
| Est. Completion | 2018-03-16 |
What the finished NCT02830282 record still lists
NCT02830282 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 21 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Blood Collection is the first listed.
NCT02830282 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02830282 about?
NCT02830282 is a clinical study titled "Surveillance Markers of Utility for Recurrence After Neoadjuvant Chemotherapy for Breast Cancer". This is a nested multicenter, prospective cohort study within the I-SPY 2 TRIAL for women undergoing neoadjuvant chemotherapy for primary breast cancer who are also undergoing definitive surgical resection and have clinical or radiographic evidence of residual tumor at the completion of chemotherapy...
What is the current status of trial NCT02830282?
This trial is currently completed. The enrollment target is 21 participants. The study started on 2013-07. Estimated completion is 2018-03-16.
What interventions are being tested in trial NCT02830282?
The interventions under investigation include: Blood Collection (OTHER).
Who is sponsoring clinical trial NCT02830282?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia